Overactive Bladder Pipeline Analysis Report 2026

Report Coverage

The overactive bladder Pipeline Analysis Report by Expert Market Research gives comprehensive insights into overactive bladder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for the overactive bladder. The overactive bladder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The overactive bladder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with overactive bladder treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to overactive bladder.

Read more about this report - Request a Free Sample

Overactive Bladder Pipeline Outlook

Overactive bladder (OAB) is typically managed with antimuscarinics or β₃-adrenergic agonists, often supplemented by behavioral therapy or third-line interventions such as botulinum toxin or neuromodulation.

Overactive bladder treatment is entering a more innovation-driven phase, supported by improved pharmacologic selectivity and patient-centric delivery approaches. The global therapeutic landscape continues to evolve, with newer agents and expanded indications reshaping management strategies. For instance, in December 2024, the vibegron (Gemtesa) β₃-agonist received expanded regulatory approval in the US for men with OAB symptoms during benign prostatic hyperplasia therapy. These developments signal a broader shift toward more tolerable, patient-friendly options and suggest a robust pipeline outlook for OAB management worldwide.

Overactive Bladder Epidemiology

Overactive Bladder (OAB) is a common urological condition characterized by urgency, frequency, and nocturia, affecting individuals across diverse populations. Epidemiological assessments indicate that OAB carries a substantial global burden, with prevalence estimates ranging widely from 2.1% to 67.0% due to differing study methodologies and demographic variations. Approximately 20% of adults worldwide are affected, with notably higher rates in women and a marked increase with advancing age and elevated body weight. These findings emphasize the condition’s widespread impact and the growing need for improved awareness and management strategies.

Overactive Bladder – Pipeline Therapeutic Assessment

Overactive Bladder Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total overactive bladder clinical trials. Phase I represents 9%, Phase III 18%, and Phase IV dominates at 47%, highlighting a pipeline that balances early development with extensive late-stage and post-marketing evaluations.

Overactive Bladder Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the overactive bladder pipeline analysis include small molecules, peptides, and combination therapies. The overactive bladder report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for overactive bladder. In July 2025, Eisai Thailand launched Beova® (vibegron) tablets in Thailand for the treatment of overactive bladder. The approval brings a new oral β₃adrenergic agonist therapy option to the Thai market. This milestone marks an important step in expanding patient access to modern OAB treatments in the region.‑adrenergic agonist therapy option to the Thai market. This milestone marks an important step in expanding patient access to modern OAB treatments in the region.

Overactive Bladder Clinical Trials – Key Players

The EMR report for the overactive bladder pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed overactive bladder therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in overactive bladder clinical trials:

• Trigone Pharma Ltd.
• TriHealth Inc.
• Sarfez Pharmaceuticals, Inc.
• Farco-Pharma GmbH
• Astellas Pharma
• AbbVie Inc.
• NeuroDesign Sciences (NDS)
• Bayer AG
• Urovant Sciences
• Pfizer Inc.

Overactive Bladder – Emerging Drugs Profile

Key Questions Answered in the Overactive Bladder Pipeline Insight Report

• Which companies/institutions are leading the overactive bladder drug development?
• Which company is leading the overactive bladder pipeline development activities?
• What is the current overactive bladder commercial assessment?
• What are the opportunities and challenges present in the overactive bladder pipeline landscape?
• What is the efficacy and safety profile of overactive bladder pipeline drugs?
• Which company is conducting major trials for overactive bladder drugs?
• Which companies/institutions are involved in overactive bladder collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in overactive bladder?

Reasons To Buy This Report

The Overactive Bladder Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for overactive bladder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into overactive bladder collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Global Clinical Trials Market

Overactive Bladder Market

Overactive Bladder Treatment Market

Overactive Bladder Epidemiology Forecast